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Abstract: Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1)
methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anticon-
vulsant drugs. It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut 
syndrome (LGS) in the United States in 2004, and released for use in Europe in 2007. In January 
2009, rufinamide was approved by the United States Food and Drug Administration for treatment 
of LGS in children 4 years of age and older. It is also approved for adjunctive treatment for partial 
seizures in adults and adolescents. Rufinamide’s efficacy mainly against atonic/tonic seizures 
in patients with LGS seems nowadays indubitable and has been confirmed both in randomized 
controlled trial and in open label extension studies. More recently, rufinamide was evaluated 
for the adjunctive treatment of childhood-onset epileptic encephalopathies and epileptic syn-
dromes other than LGS, including epileptic spasms, multifocal epileptic encephalopathy with 
spasm/tonic seizures, myoclonic-astatic epilepsy, Dravet syndrome and malignant migrating 
partial seizures in infancy. This review updates the existing literature data on the efficacy and 
safety/tolerability of rufinamide in childhood-onset epilepsy syndromes.
Keywords: rufinamide, Lennox-Gastaut syndrome, epileptic encephalopathy, myoclonic-
astatic syndrome, Dravet syndrome, malignant migrating partial seizures in infancy, refractory 
childhood epilepsy
Introduction
Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1)
methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from 
other antiepileptic drugs (AEDs). In experimental models rufinamide was effec-
tive in suppressing neuronal hyper-excitability by prolonging the inactivation of 
voltage-gated sodium channels.1 It also showed a broad spectrum of anticonvulsant 
activity, suppressing maximal electroconvulsive shock-induced seizures in both rats 
and mice models, and in PTZ-test in mice.2 Rufinamide is well absorbed after oral 
  administration, demonstrates low protein binding, and is metabolized by enzymatic 
hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug 
interaction potential.3
It was granted orphan drug status for the adjunctive treatment of Lennox-Gastaut 
syndrome (LGS) in the United States in 2004, and released for use in Europe in 
2007. In January 2009, rufinamide was approved by the United States Food and Drug 
Administration for treatment of LGS in children 4 years and older. It is also approved 
for adjunctive treatment for partial seizures in adults and adolescents.4Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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In 3 randomized controlled trials, rufinamide was 
  effective and safe for the adjunctive treatment of partial 
seizures in adults and adolescents,4,5 and the treatment of 
generalized seizures associated with LGS.6
Until recently, few studies were available on rufinamide 
for the treatment of epileptic encephalopathies and specific 
childhood-onset epileptic syndromes other than LGS.7–11 The 
purpose of this review is to report an update of the existing 
literature data on the efficacy and safety/tolerability of rufi-
namide in childhood-onset epilepsy syndromes.
Rufinamide and Lennox-Gastaut 
syndrome
LGS, one of the catastrophic epilepsies of childhood, is 
classified by the International League against Epilepsy 
as a symptomatic generalized epilepsy syndrome.12 It is 
characterized by the electroclinical features of (1) elec-
troencephalogram (EEG) showing abnormal background, 
diffuse slow-spike-and-wave complexes (1.5–2.5 Hz), and 
paroxysmal fast rhythms (10 Hz), although the latter may 
only occur in sleep; (2) multiple types of epileptic seizures 
typically including tonic, typical absences, and drop-attacks; 
some patients may develop myoclonic, generalized tonic-
clonic, or partial seizures; and (3) slow mental development 
and/or behavioral disturbance. Over 75% of children with 
LGS have an identifiable cause (symptomatic or presumed 
symptomatic/cryptogenic). These include both congenital 
and acquired etiologies such as cortical maldevelopment and 
neuronal migration disorders, perinatal hypoxia/ischemia, 
infections of the central nervous system, or neurometabolic 
disorders.
West syndrome is present in the clinical history of about 
20% of these patients. LGS is notoriously drug-resistant and 
80% to 90% of patients continue having seizures in adult life 
and nearly all (85%–90%) have severely impaired cognition 
and behavior, finally requiring to be institutionalized.
Many treatment attempts in LGS are anecdotal and 
empirical and AED therapy nearly always fails to control 
seizures completely, although a reduction in seizures, usually 
temporarily, may be achieved. A rational polytherapy is then 
the rule, including old and new antiepileptic drugs.
Only one double-blind, randomized, placebo-controlled 
study is so far available on rufinamide for the treatment of 
Lennox-Gastaut refractory seizures.6 Another three, uncon-
trolled, open label trials with rufinamide have been published, 
of which 1 is a long-term, open-label extension study.13–15
The unique randomized controlled trial by Glauser et al6 
involved 138 patients between ages of four and 30 years 
who had LGS diagnoses for a median of 7.5 years. About 
  one-third of participants were under twelve years of age. 
After a 28-day baseline period, 138 patients received either 
rufinamide (n = 74) or placebo (n = 64) in addition to 
their other AEDs. After a 12-week parallel group treat-
ment (2-week titration, 10-week maintenance), the median 
  percentage reduction in total seizure frequency was greater 
in the rufinamide therapy group than in the placebo group 
(32.7% vs 11.7%, P = 0.0015), and in tonic-atonic (drop-
attack) seizure frequency with rufinamide (42.5% median 
percentage reduction) vs placebo (1.4% increase). The rufi-
namide group had a greater improvement in seizure severity 
(P = 0.0041) and a higher 50% responder rate compared 
with placebo for total seizures (P = 0.0045) and tonic-atonic 
seizures (P = 0.002). Tolerability profile of rufinamide was 
overall favorable with somnolence (24.3% on rufinamide 
vs 12.5% on placebo) and vomiting (21.6% vs 6.3%), being 
the most common adverse events.
The long-term efficacy and tolerability of rufinamide in 
124 of the 138 patients with LGS who had previously com-
pleted a 12-week double-blind study, were reported recently 
by Kluger et al.14 During the extension study, the median dose 
of rufinamide was 1800 mg/day (52.9 mg/kg/day). Overall, 
patients were treated with rufinamide for a median (range) 
of 432 (10–1149) days. Rufinamide was added to 1 (n = 13), 
2 (n = 69) or 3 (n = 42) concomitant AEDs at the start of the 
extension phase.
At the time of the study termination, 42 patients (32.9%) 
were still receiving rufinamide and 82 patients (66.1%) had 
discontinued due to: poor efficacy (n = 51), adverse events 
(n = 12) or other reasons (n = 19). During the last 12 months 
of treatment, 41.0% and 47.9% of patients had $50% reduc-
tion in total and tonic-atonic seizure frequency, respectively. 
The most common adverse events (AEs) were vomiting 
(30.6%) and pyrexia (25.8%). It was concluded that rufi-
namide appeared to be an effective long-term adjunctive 
therapy for the treatment of the LGS-associated seizures in 
children and young adults.
Other data come from two European studies,13,15 and 
one published in the US.16 The first study from Europe,13 
using observational retrospective data from multiple centers, 
examined the effectiveness of rufinamide in 45 children and 
15 adults with refractory epilepsy, including 31 patients with 
LGS. After an observation period of 12 weeks, the highest 
response rate was observed in patients with LGS (17/31, 
54.8%) and the lowest in patients with partial epilepsy (4/17; 
23.5%). Four of the five seizure-free patients had LGS. 
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were observed for tonic seizures (45.0%) and drop-attacks 
(47.1%). Investigators found fatigue, vomiting and anorexia 
in 10% to 20% of patients but no serious adverse effects. The 
results of this study led authors to conclude that the efficacy 
of rufinamide in patients with generalized epilepsy was 
comparable to that in patients with LGS, whereas this drug 
was less effective in patients with partial epilepsy.
In 2010, the first Italian multicenter experience with 
rufinamide in children and adults with LG syndrome was 
also reported.15 In a prospective, add-on, open-label treat-
ment study, 43 patients (26 males), aged between four 
and 34 years (mean 15.9 ± 7.3, median 15.0), were treated 
with rufinamide for a mean period of 12.3 months (range 
3–21 months). Twenty patients of 43 were diagnosed as 
cryptogenic. After a mean follow-up period of 12.3 months 
(range 3–21 months), the response rate ($50% decrease in 
countable seizures) was 60.5% in total, with a final mean 
dose of rufinamide of 33.5 mg/kg/24 hours (range 1.5–60) 
if combined with valproic acid, and 54.5 mg/kg/24 hours 
(range 21.8–85.6) without valproic acid. A 50% to 99% 
reduction in seizure frequency was experienced by 51.1% 
and a complete seizure control in the last 4 weeks’ follow-up 
was experienced by 9.3% of patients.
Drop attacks and tonic seizures were most improved by 
rufinamide adjunctive therapy.
Further data, also encouraging for LGS patients, were 
more recently reported in a retrospective observational 
study by Vendrame et al.16 In 26 patients with LGS out of 
91 pediatric patients with a median follow-up of 12 years 
(range 1–27 years), 38.4% showed a $50% decrease in 
seizure frequency, with a maximal responder rate in tonic-
atonic and partial seizures. This trial confirmed rufinamide 
to be particularly effective against drop-attacks and/or tonic 
seizures in patients with LGS.
Rufinamide and other epileptic 
encephalopathies
Besides LGS, the epileptic encephalopathies of infancy and 
early childhood, often defined as catastrophic epilepsies 
because of the significant cognitive and neurological morbidity 
not rarely associated with death, comprise very early epileptic 
encephalopathies, West syndrome, severe myoclonic epilepsy 
of infancy (Dravet syndrome), refractory myoclonic-astatic 
epilepsy (Doose syndrome), and the recently recognized 
  syndrome of malignant migrating partial seizure in infancy.
Epileptic (infantile) spasms are the defining clinical 
manifestation of West syndrome. The symptomatic form of 
West syndrome is by far the commonest detected cause and 
probably accounts for 80% of all cases. Several pre-, peri- 
and postnatal insults are responsible, ranging from hypoxia-
ischemia, infections, trauma, and intracranial hemorrhage 
to malformations of cortical development, neurocutaneous 
diseases, genetic and chromosomal abnormalities and, less 
often, inborn errors of metabolism.
Idiopathic West syndrome, with normal premorbid 
development and possible hereditary predisposition is far 
less frequent, accounting for 5% to 30% of all cases.
Treatment options for epileptic spasms are limited17 and 
effective treatment of spasm remains an important unmet 
medical need,18 as long-term developmental and cognitive 
outcomes for patients with spasms is likely to be improved 
with effective control of spasms.
Recently, Olson et al8 reported on a retrospective review 
of their experience with rufinamide as adjunctive therapy in 
38 patients with refractory epileptic spasms, aged 17 months 
to 23 years (median seven years). Rufinamide was added to 
a median number of three AEDs, at the median starting dose 
of 9 mg/kg/day (range 2–8), while the median final treatment 
dose was 39 mg/kg/day (range 8–92).
Median duration of follow-up since starting rufinamide 
was 171 days (range 10–408). The responder rate, defined 
as $50% reduction in spasms, was 53%. Nine patients (24%) 
achieved a reduction in spasms $90%, and two patients 
(5%) achieved $99% reduction in spasms. Rufinamide was 
discontinued in 7 of 38 patients (18%) because of lack of 
efficacy, worsening seizures, or other side effects. Minor 
side effects were reported in 14 of 38 patients (37%), includ-
ing increased seizure frequency at high dose (5), decreased 
appetite (3), sedation (3), eyes crossing (1), vomiting (1).
A number of limitations may be stressed in the context 
of this study: its retrospective nature, the quantification of 
spasm frequency before and after treatment, essentially 
based on clinical notes and more rarely on EEG data, and the 
high refractoriness of patients referred to a tertiary epilepsy 
center. Furthemore, it must be underlined that 1 patient 
only had hypsarrhythmia at the time of treatment with rufi-
namide, and only 9 other patients had a previous history of 
  hypsarrhythmia. The remaining 29 patients had a diagnosis 
of LGS (10), Ohtahara syndrome (1), unclassified epilepsy 
(15), and migrating partial seizure in infancy (3). Last, epi-
leptic spasms lasting 1 to 15 seconds seemed more often to 
be tonic seizures rather than infantile spasms.
In another study by Coppola et al,7 rufinamide was 
assessed for the adjunctive therapy of epileptic encephalopa-
thies and generalized epilepsies other than LGS, including 
severe multifocal encephalopathy with spasm/tonic seizures, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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refractory myoclonic-astatic epilepsy, Dravet syndrome, 
and malignant migrating partial seizures in infancy. This 
prospective, open-label study of rufinamide as adjunctive 
therapy reports a decrease in seizure frequency in seven of 
the 22 patients (31.8%) with multifocal encephalopathies 
with spasms and tonic seizures, and in seven of 11 patients 
(63.8%) with (bi)frontal spike-wave discharges.
Concerning seizure types, this study confirms rufinamide 
to be particularly effective against drop-attacks and, to a 
lesser extent, tonic and tonic-clonic seizures. Furthermore, 
response to rufinamide was less sustained in this kind of 
encephalopathy than in patients with LGS (40% vs 55% as 
reported by Glauser et al6 and Kluger et al.14
Kluger et al13,14 reported another seven patients with 
  otherwise unclassified cryptogenic or symptomatic general-
ized epilepsies, and treated with rufinamide. These authors 
found an unexpectedly high rate of responders in this small 
group of patients (42.8%), with one patient seizure-free 
and two with 50%–75% seizure decrease. In the long-term 
assessment,19 after 18 months, two of these patients were still 
on rufinamide and 1 of them was seizure-free.
Myoclonic-astatic epilepsy, also known as Doose syn-
drome, is a generalized epilepsy syndrome in children aged 
one to six years which occurs in 1.6% to 4% of all newly diag-
nosed epilepsies in children and adolescents.20 It is character-
ized by a normal early childhood development before the onset 
of epilepsy and the lack of organic cerebral   abnormalities. 
The main seizure types (myoclonic,   myoclonic-astatic, or 
astatic seizures) start in the first five years of life. In the EEG 
a presence of generalized 2 to 3 Hz spike- or polyspike-wave 
complexes without focal spike discharges is seen. In the dif-
ferential diagnosis severe and benign myoclonic epilepsy in 
infancy and early childhood, additionally cryptogenic LGS 
as well as atypical benign partial epilepsy/pseudo LGS, and 
other symptomatic/cryptogenic epilepsies such as frontal 
lobe epilepsy must be excluded.21 The course of myoclonic-
astatic epilepsy in general is unpredictable. In some patients 
it is self-limited and the seizures disappear. Other children 
have a more severe course with prolonged episodes of 
nonconvulsive status epilepticus leading to cognitive and 
behavioral impairment and mental retardation in parts turning 
into a LGS.22 Treatment of myoclonic-astatic epilepsy often 
remains challenging with valproic acid as first line drug.23 
Add-on therapy with lamotrigine which has shown efficacy 
especially in myoclonic and myoclonic-astatic seizures is 
another option, but the slow titration of lamotrigine limits 
its use in patients with lots of seizures or nonconvulsive 
status epilepticus. Ethosuximide is recommended especially 
in absences and myoclonic seizures. The use of small doses 
of benzodiazepines, levetiracetam, and topiramate are other 
alternatives.21 Oguni and colleagues23 recommended as 
most effective treatment for myoclonic astatic seizures the 
ketogenic diet, followed by adrenocorticotropic hormone 
(ACTH) and ethosuximide. Especially in the beginning of 
myoclonic-astatic epilepsy the differential diagnosis of LGS 
may be very difficult. This has been reflected in the past by 
summarizing both these epilepsy forms under the rubric of 
“myoclonic epilepsies”.24
For myoclonic-astatic epilepsy, four patients were reported 
in more heterogeneous series (three by Kluger et al13 and one 
by Coppola et al7), and a further eight refractory patients with 
myoclonic-astatic epilepsy by Stupnagel et al.9 The first four 
patients were all responders with a 50% to 99% improvement 
in seizure frequency after a follow-up of 12 to 36 months.
After a follow-up of 18 months, all three patients by 
Kluger et al19 were still taking rufinamide and 1 of them 
showed a .50% seizure reduction. More recently, Von 
Stupnagel et al9 evaluated the effectiveness and tolerabil-
ity of rufinamide in eight children with pharmacoresistant 
myoclonic-astatic epilepsy in a retrospective European 
multicentric study. Overall, the responder rate after 3 months 
(reduction of seizure frequency $50% in comparison with 
4 weeks before starting therapy with rufinamide) was 87.5%. 
Six of the initial responders showed some loss of efficacy 
after 6 months (decrease in the reduction of seizure frequency 
from initially 75% to 50%, one patient no longer showed 
a therapeutic effect), while responder rate after 18 months 
was 33%. The authors concluded that in this small group of 
patients with myoclonic-astatic epilepsy, rufinamide may 
be effective especially for drop-attacks but with a loss of 
long-term efficacy.
Dravet syndrome (severe myoclonic epilepsy of infancy) 
is characterized by prolonged febrile seizures starting at about 
the age of 6 months. Other types of seizures might be pres-
ent at onset or develop later including myoclonic seizures, 
complex partial seizures, generalized tonic-clonic seizures 
and, sometimes, alternating hemiclonic seizures. Although 
psychomotor development is initially normal, a plateau 
occurs usually in the second year of life with subsequent 
intellectual disability.25 Mutations in SCN1A coding for the 
alpha-1 subunit of the voltage-gated sodium channel can be 
detected in up to 80% of children.26–28 Dravet syndrome is 
a difficult-to-treat epilepsy syndrome. Treatment of Dravet 
syndrome remains challenging and is based on the use of 
a maintenance AEDs therapy, prevention of infectious 
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treatment with benzodiazepines. Randomized controlled 
studies of AED use in Dravet syndrome have only been 
published for add-on treatment with stiripentol.29
The first data reported on Dravet syndrome and rufin-
amide were for six patients, two reported by Kluger et al,13 
and four by Coppola et al.7 One of two patients initially 
reported by Kluger et al,13 with SCN1A mutation and Dravet 
syndrome, had a 90% reduction in generalized tonic-clonic 
seizures. This patient was severally handicapped and had been 
refractory to previous treatment with eleven conventional 
AEDs. Though still on rufinamide after 18 months, this 
patient was no longer considered as a responder.19 One of the 
four patients with Dravet syndrome reported by   Coppola et al7 
had a 25% to 49% seizure reduction after a mean 11.4 month 
observational period. Seizure frequency remained unchanged 
in another one and increased in other two. Recently,   Mueller 
et al11 reported efficacy and tolerability of rufinamide in 
20 patients with Dravet syndrome and refractory seizures 
in a retrospective European multicenter study. Sixteen of 
20 patients had a SCN1A mutation. The responder rate was 
20% after 6 months, and 5% after 34 months. The retention 
rate was 45% after 6 months, 15% after 18 months, and 
15% after 34 months. Rufinamide treatment was stopped 
due to seizure aggravation in about one-third of the patients. 
Therefore, these authors state that rufinamide does not seem 
to be a suitable option for long-term treatment in patients 
with Dravet syndrome.
Malignant migrating partial seizures in infancy (MMPSI) 
is a rare and severe syndrome first reported in 1995 by 
  Coppola et al.30 MMPSI was included among the childhood 
epilepsy syndromes in the development of the proposal to 
revise the International League Against Epilepsy (ILAE) 
classification of epilepsies and epilepsy syndromes12 and, 
more recently, placed between the Ohtahara syndrome and 
West syndrome in the list of electroclinical syndromes and 
other epilepsies presented by age at onset, as provided by the 
ILAE Commission on Classification and Terminology.20,31
The main features of the syndrome are seizure onset 
within the first semester of life in a previously normal child, 
focal seizures that typically migrate from one area to another 
in one hemisphere or from one hemisphere to the other, 
marked drug resistance, and severe long-term outcome.30
Since 1995, more than 60 cases have been reported32–36 
and, from the first series,30 a few cases with seizure onset in 
the first day of life34 or with a less unfavorable outcome have 
been described.33,35
Etiology remains largely unknown. The hypothesis of 
a genetic component has failed to be proved despite the 
genetic testing of a large series for several ion channel 
genes.37 To date, familial recurrence of this syndrome has 
not been reported.
Very recently, Vendrame et al10 reported the   retrospective 
data on the efficacy of rufinamide in five infants (three 
males) with malignant migrating partial epilepsy of infancy 
(MMPEI), aged between 25 and 41 months (median 
30 months). Age at seizure onset ranged between 15 days and 
3.5 months (median 1.5 month). Rufinamide was added to one 
of two AEDs (levetiracetam, 2; lamotrigine,1; topiramate,1; 
zonisamide,1) in four children and given alone in another 
one, at the daily dose of 5 to 75 mg/kg.
Two of the five cases had a dramatic response to rufin-
amide with a .50% reduction in seizure frequency and no 
side effects. In another case rufinamide was discontinued 
because of vomiting, and in the other two cases rufinamide 
led to seizure worsening (in one patient as monotherapy), 
and had to be withdrawn within 2 to 4 weeks. Reported side 
effects were vomiting and loss of appetite, similar to side 
effects that have been previously described. In conclusion, 
rufinamide showed good efficacy and tolerability in two of 
the five cases with MMPEI. Although limited, these obser-
vations provide hope for a novel therapeutic option in this 
otherwise devastating epileptic syndrome.
Rufinamide in partial seizures
Data on rufinamide for the treatment of partial seizures in 
the pediatric population are currently scarse (no more than 
60 patients) and have to be pooled out from a few series.
Kluger et al13 in a heterogeneous group of 45 children and 
15 adults with refractory epilepsy, reported that the lowest 
responder rate (23.5%) was found among the 17 patients with 
partial epilepsy. Data were collected after a 3-month observa-
tion period during which patients received a mean final dose 
of rufinamide of 35.6 ± 17.3 mg/kg/day, generally achieved 
within 4 weeks. Add-on therapy with rufinamide was usually 
initiated at 10 mg/kg/day and valproic acid and clobazam 
were the most commonly used concomitant AEDs.
Indeed, of the four responders, three had a seizure reduction 
of 50%–75% and 1 of 75%–99%. Accordingly, with respect to 
disabling seizure types, the lowest responder rates were also 
observed for partial seizures (26.0%), while the highest for 
tonic fits and drop-attacks (45% and 47.1%, respectively).
Indeed, three of four responders had a seizure decrease 
of 50% to 75% and another 1 of 75% to 99%.
It is, however, unknown how many of these patients 
belong to pediatric age. Accordingly, these authors state 
that their result is in concordance with previous studies Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  demonstrating responder rates between 11.0% and 20.4% in 
adults and adolescents with partial onset seizures.4,38
The same authors19 in an extension follow-up study of 
the same series of 60 patients reported the worst outcome 
after 18 months for the patients with partial seizures (11.8%), 
of whom only two of 17 were still responders and three of 
17 (17.6%) were still taking rufinamide. On the contrary, 
the retention rate after 18 months of the other generalized 
epilepsy syndromes including Lennox-Gastaut syndrome 
was 51.6%.
As to the origin of focal seizures, those starting from 
frontal lobes, even in patients with multifocal epileptic 
encephalopathies, were particularly sensitive to rufinamide 
treatment.7 In more detail, in the group with (bi)frontal spike-
wave discharges, seven of eleven patients (63.6%), all of 
them with drop-attacks, had a seizure reduction of $50%; 
conversely, in the group without frontal discharges, in 
which focal and tonic seizures were most frequent, seven of 
22 patients (31.8%) showed a $50% seizure decrease.
Last, Vendrame et al,16 in a retrospective analysis of 
77 patients with diverse refractory epilepsy syndromes 
and receiving rufinamide as adjunctive therapy, reported 
the   highest responder rate in focal cryptogenic epilepsies 
(83.3% of patients with $50% of response rate), and in 
diverse   seizure types, with the highest responder rate in 
tonic/atonic and partial seizures (48.6% and 46.7% of 
patients with $50% response rate, respectively). Of note is 
that the number of patients with cryptogenic focal seizures 
is small (twelve cases), while a $50% seizure reduction in 
symptomatic partial seizures was present in only 31.3% of 
cases. Further, an early response was evident at doses as low 
as 10 mg/kg/day, with no further benefits above the recom-
mended dose. Similarly, no correlation was evident between 
decrease in seizure frequency and number or type of AEDs 
used together with rufinamide.
Safety and tolerability of rufinamide
A recent, pooled analysis of seven clinical studies by 
  Wheless et al39 comprising 212 rufinamide-treated (age 
range 3–16 years) and 197 placebo patients (age range 
4–17 years) in the double-blind studies, and 391 patients 
receiving rufinamide in the double-blind and/or open label 
extensions, the most common adverse effects observed in 
rufinamide-treated patients in the double-blind studies were 
somnolence, vomiting, and headache. Changes in labora-
tory values, vital signs, and weight were generally clinically 
insignificant.   Accordingly, these authors state that rufinamide 
in pediatric patients, mainly as adjunctive therapy, shows a 
favorable safety and tolerability profile. An up-to-date review 
of adverse events in pediatric patients treated with rufinamide 
in eleven clinical studies (Table 1) seems to confirm previous 
data, even extending the favorable tolerability and safety 
profile of rufinamide to long-term administration.
Conclusion
Data emerging from literature confirm that rufinamide 
deserves a privileged role in the treatment of LGS, for which 
it is granted orphan drug status. Efficacy of rufinamide 
mostly against atonic-tonic seizures in these patients is also 
undoubted, and explains why this drug is now considered a 
second-line therapy together with lamotrigine, levetiracetam, 
topiramate, and zonisamide, to be combined with valproic 
acid, which still remains the first-line therapy option.40
Probably, rufinamide should be preferred to other drugs 
such as lamotrigine and topiramate when drop-attacks and/
or tonic fits are the main seizure type and, of course, before 
felbamate, other newer anticonvulsant drugs, vagus nerve 
stimulation, or corpus callosotomy is considered.
Overall, rufinamide may be considered a second-line 
therapy for LGS to be added to valproic acid, which remains 
the first-choice drug. Rufinamide should be considered 
among one or two of the following: lamotrigine, levetirac-
etam, topiramate, and zonisamide, and should be probably 
preferred early if atonic-tonic fits occur.
It has in addition the advantage of full therapeutic dos-
ing within 1 week, whereas other approved medications, 
lamotrigine and topiramate, can take up to 2 months to reach 
therapeutic values.
Preliminary data also seem to confirm the efficacy of 
rufinamide in epileptic encephalopathies other than LGS, 
including myoclonic-astatic epilepsy and Lennox-like mul-
tifocal encephalopathies, particularly those with (bi)frontal 
spike and wave discharges and tonic/atonic seizures. Less 
encouraging appears to be the efficacy of rufinamide in 
Dravet syndrome and malignant migrating partial seizures 
in infancy. Overall, rufinamide appears to be less effective 
against focal-onset seizures compared with generalized 
encephalopathies, though this issue is still controversial 
and further studies are warranted especially in pediatric 
patients.
Titration schedule should be as slow as possible, though 
a short escalation period with increasing dose at each 3-day 
interval is usually recommended in the packet insert. A slow 
titration phase improves tolerability, allowing assessment of 
clinical efficacy at low doses in some patients and detection 
of seizure worsening in others.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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As regards the daily dose, an early response may be 
  evident at a dose as low as 10 mg/kg/day or even less. A mean 
maintenance dose of 35 ± 20 mg/kg/day seems most used, 
though the optimal dose should be tailored according to 
clinical response.
So far, little is known about therapeutic blood levels, 
though the mean plasma rufinamide concentration to reduce 
seizure frequency by 25% to 50% is predicted to be 15 to 
30 µg/mL.3
Overall, rufinamide is a well-tolerated anticonvulsant 
drug, and most expected adverse side effects are vomiting, 
drowsiness, irritability, and loss of appetite. They are usually 
mild and transient.
For now, rufinamide is a welcome addition to the treat-
ment armamentarium for refractory childhood epilepsy and 
further studies are needed to better shape its clinical efficacy 
in children with epilepsy.
Disclosure
The author declares no conflicts of interest.
References
  1.  McLean MHJ, Schmutz M, Pozza M, et al. The influence of   rufinamide 
on sodium currents and action potential firing in rodent neurons 
[abstract]. Epilepsia. 2005;46(Suppl 8):296.
  2.  White HS, Schmutz M, Pozza M, Wolf H, Stables J, Kupfnerg H. The 
anticonvulsant profile and tolerability of rufinamide in mice and rats 
[abstract]. Epilepsia. 2005;46(Suppl 8):280.
  3.  Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical phar-
macokinetics and concentration-response relationships in patients with 
epilepsy. Epilepsia. 2008;49:1123–1141.
  4.  Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunc-
tive treatment of partial seizures in adults and adolescents: a randomized 
placebo-controlled trial. Epilepsia. 2009;50:1899–1909.
  5.  Palhagen S, Canger R, Henriksen O, van Parys JA, Riviere ME, 
Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof 
of principle trial in patients with epilepsy. Epilepsy Res. 2001;43: 
115–124.
  6.  Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. 
Rufinamide for generalized seizures associated with Lennox-Gastaut 
syndrome. Neurology. 2008;70:1950–1958.
  7.  Coppola G, Grosso S, Franzoni E, et al. Rufinamide in refractory child-
hood epileptic encephalopathies other than Lennox-Gastaut sindrome. 
Eur J Neurol. 2011;18:246–251.
  8.  Olson HE, Loddenkemper T, Vendrame M, et al. Rufinamide for the 
treatment of epileptic spasms. Epilepsy Behav. 2011;20:344–348.
  9.  Von Stupnagel C, Coppola G, Striano P, Muller A, Staudt M, Kluger G. 
First long-term experience with the orphan drug rufinamide in children 
with myoclonic-astatic epilepsy (Doose syndrome). Eur J Ped Neurol. 
2011. [Epub ahead of press].
  10.  Vendrame M, Poduri A, Loddenkemper T, Kluger G, Coppola G, 
Kothare SV. Treatment of malignant migrating partial epilepsy of 
infancy with rufinamide: report of five cases. Epileptic Disord. 2011; 
13:18–21.
  11.  Mueller A, Boor R, Coppola G, et al. Low long-term efficacy and 
tolerability of add-on rufinamide in patients with Dravet syndrome. 
Epilepsy Behav. 2011. [Epub ahead of press].
  12.  Engel J Jr. A proposed diagnostic scheme for people with epileptic 
seizures and with epilepsy: report of the ILAE Task Force on clas-
sification and terminology. Epilepsia. 2001;42:796–803.
  13.  Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and toler-
ability of rufinamide in children and adults with refractory epilepsy: 
first European experience. Epilepsy Behav. 2009;14:491–495.
  14.  Kluger G, Glauser T, Krauss G, et al. Adjunctive rufinamide in Lennox-
Gastaut syndrome: a long-term, open-label extension study. Acta Neurol 
Scand. 2010;122:202–208.
  15.  Coppola G, Grosso S, Franzoni, et al. Rufinamide in children and adults 
with Lennox-Gastaut syndrome: first Italian multicenter experience. 
Seizure. 2010;19:587–591.
  16.  Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with 
rufinamide in a pediatric population: a single center’s experience. 
Pediatr Neurol. 2010;43:155–158.
  17.  Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a US 
consensus report. Epilepsia. 2010;36:15.
  18.  Coppola G, Pascotto A. The medical treatment of infantile spasms. 
In: Guzzetta F, Dalla Bernardina B, Guerrini R, editors. Progress in 
Epileptic Spasms and West Syndrome: Progress in Epilepsic Disorders. 
Paris: John Libbey; 2007:153–173.
  19.  Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term 
experience with the orphan drug rufinamide in childhood-onset refrac-
tory epilepsy. Epilepsy Behav. 2010;17:546–548.
  20.  Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and 
concepts for organization of seizures and epilepsies: report of the ILAE 
Commission on Classification and Terminology, 2005–2009. Epilepsia. 
2010;51:676–685.
  21.  Guerrini R, Parmeggiani L, Bonanni P, Kaminska A, Dulac O. 
  Myocloni astatic epilepsy. In: Roger J, Bureau M, Dravet C, Genton P, 
Tassinari CA, Wolf P, editors. Epileptic Syndromes in Infancy, Child-
hood and Adolescence. 4th ed. Paris: John Libbey; 2005:115–124.
  22.  Doose H. Myoclonic astatic epilepsy of early childhood. In: Roger J, 
Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, editors. Epileptic 
Syndromes in Infancy, Childhood and Adolescence. 2nd ed. London: 
John Libbey; 1992:103–114.
  23.  Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term progno-
sis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics. 
2002;33:122–132.
  24.  Bonanni P, Parmeggiani L, Guerrini R. Different neurophysiologic 
patterns of myoclonus characterize Lennox-Gastaut syndrome and 
myoclonic astatic epilepsy. Epilepsia. 2002;43:609–615.
  25.  Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic 
epilepsy in infancy: Dravet syndrome: Adv Neurol. 2005;95:71–102.
  26.  Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, 
De Jonghe P. De novo mutations in the sodium-channel gene SCN1A 
cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001; 
68:1327–1332.
  27.  Nabbout R, Dulac O. Epileptic encephalopathies: a brief overview.   
J Clin Neurophysiol. 2003;20:393–397.
  28.  Mulley JC, Nelson P, Guerrero S, et al. A new molecular mechanism 
for severe myoclonic epilepsy of infancy: exonic deletions in SCN1A. 
Neurology. 2006;67:1094–1095.
  29.  Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe 
myoclonic epilepsy in infancy: a randomised placebo-controlled 
syndrome-dedicated trial. STICLO study group. Lancet. 2000;356: 
1638–1642.
  30.  Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial 
seizures in infancy: a malignant disorder with developmental arrest. 
Epilepsia. 1995;36:1017–1024.
  31.  Engel J Jr. Report of the ILAE Classification Core Group. Epilepsia. 
2006;47:1558–1568.
  32.  Dulac O. Malignant migrating partial seizures in infancy. In: Roger J, 
Bureau M, Dravet Ch, Genton P, Tassinari CA, Wolf P, editors.   Epileptic 
Syndromes in Infancy, Childhood and Adolescence. 4th ed. Paris: John 
Libbey; 2005:73–76.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
407
Rufinamide in childhood epilepsy
  33.  Marsh E, Melamed SE, Barron T, et al. Migrating partial seizures in 
infancy: expanding the phenotype of a rare seizure syndrome. Epilepsia. 
2005;46:568–572.
  34.  Hmaimess G, Kadhim H, Nassogne MC, Bonnier C, van Rijckevorsel K. 
Levetiracetam in a neonate with malignant migrating partial seizures. 
Pediatr Neurol. 2006;34:55–59.
  35.  Caraballo RH, Fontana E, Darra F, et al. Migrating focal seizures in 
infancy: analysis of the electroclinical patterns in 17 patients. J Child 
Neurol. 2008;23:497–506.
  36.  Coppola G. Malignant migrating partial seizures in infancy: an epi-
lepsy syndrome of unknown etiology. Epilepsia. 2009;50(Suppl 5): 
49–51.
  37.  Coppola G, Veggiotti P, Del Giudice EM, et al. Mutational scanning 
of potassium, sodium and chloride ion channels in malignant migrating 
partial seizures in infancy. Brain Dev. 2007;28:76–79.
  38.  Elger CE, Stefan H, Mann A, Narurkar M, Sun Y, Perdomo C.   
A 24-week multicenter, randomized, double-blind, parallel-group, dose-
ranging study of rufinamide in adults and adolescents with inadequately 
controlled partial seizures. Epilepsy Res. 2010;88:255–263.
  39.  Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. 
Safety and tolerability of rufinamide in children with epilepsy: a pooled 
analysis of 7 clinical studies. J Child Neurol. 2009;24:1520–1525.
  40.  Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). 
Eur J Ped Neurol. 2009;13:493–504.